Skip to main content

Research Focus Areas

Our faculty, residents and fellows are committed to the research enterprise, and they are actively leading and contributing to innovative studies and clinical trials in a wide range of sub-specialties.


Our expert faculty members are committed to improving the quality of life for people with epilepsy. One crucial way we do this is through our research and clinical trials. But we can't do it alone. We need your help!

Who can participate?
Truly anyone who is interested in participating in clinical research can volunteer. In fact, millions of people just like you volunteer to participate in research studies every day.

Why should you volunteer?
Clinical research is the final step of all medical advances. Research helps us look at new ways to prevent, diagnose or treat disease. Each research study helps doctors and scientists understand epilepsy better. Participating in research is a way to give back to the broader epilepsy community and to improve future epilepsy treatments. We invite anyone interested in volunteering for one of our research studies to get involved. Together we can help make a difference in the lives of people with epilepsy.

Our research opportunities
We offer research opportunities in a variety of areas. We are actively enrolling participants in multiple ongoing studies.

  • Clinical trials
    • Epilepsy Medicine Treatment Trials
      • A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy ( Identifier: NCT03796962)
        • A Brief Description: The XEN1101 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of increasing doses of XEN1101 administered as adjunctive treatment in adult patients (aged 18-75 years) diagnosed with focal epilepsy taking 1-3 antiepileptic drugs, followed by an optional open-label extension.
        • Time Frame In the double-blind treatment period the time frame is from baseline (8 weeks prior to Day 0) through to the final dose (up to Day 56).
        • Compensation: Each visit, including screening and baseline, will be compensated with $150 for the participant's time.
    • Epilepsy Surgery Outcomes
      • Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN) ( Identifier: NCT02392078)
        • A Brief Description: Laser interstitial thermal therapy (LITT) is a minimally invasive epilepsy surgery technique. It is also called laser ablation. LAANTERN is a prospective, multi-center registry that includes data collection up to 5 years to evaluate safety, quality of life, and procedural outcomes after LITT for epilepsy. There is a separate arm in this study evaluating intracranial tumors as well.
        • Time Frame: There is a baseline appointment to capture data pre-operative appointment to compare post-operative data to. Following the operation there is a 1 month, 3 month, 6 month, 12 month, 24 month, 36 month, 48 month, and finally a 60 month post-operative visit.
        • Compensation: The participant will be compensated $50 for each post-operative visit. The participant will have the opportunity to collect $400 if they attend every visit.
      • Medtronic Deep Brain Stimulation (DBS) Therapy for Epilepsy Post-Approval Study (EPAS) ( Identifier: NCT03900468)
        • A Brief Description: The purpose of this post-approval study is to further evaluate the long-term safety and effectiveness of Medtronic DBS therapy for epilepsy on seizure reduction in newly implanted participants through 3 years of follow-up in different geographic populations.
        • Time Frame: Once enrolled, this study takes place a little over the course of three years. There will be one visit two weeks post-operation to activate the DBS device. After that there will be a 3 month, 6 month, 9 month, 12 month, 24 month, and 36 month visit.
        • Compensation: Compensation for this study is dependent on participation. Please ask for more details.
  • Improving Understanding of Epilepsy
    • Written Language Abilities During Aphasic Seizure
      • Brief Description: Participant that are treated at The University of Kansas Health System Epilepsy or Neurology Clinics and those that are treated in the inpatient epilepsy monitoring unit will be assessed for the type of seizure they have (done routinely). The aim of the study is to assess what writing ability is like during aphasic seizures. The hypothesis is that aphasic seizures would also affect written language (agraphia).

All our research studies happen here at KU Medical Center, one of 36 U.S. public institutions in the prestigious Association of American Universities, an invitation-only organization for the nation's top research universities. We also partner with The University of Kansas Health System, which provides patient care and has the only Level 4 Epilepsy Center in the state of Kansas.

Here's how you can get involved
To learn more about available epilepsy research opportunities and your eligibility for studies, please contact Lauren Holland, Clinical Research Coordinator, 913-634-2893 and or speak with your epilepsy doctor.

Epilepsy research studies and publications

Dementia/Alzheimer's Disease

As one of only 31 Alzheimer's Disease Centers designated nationally by the National Institutes of Health, the University of Kansas Alzheimer's Disease Center has long been a leader in ground-breaking dementia research. The KU ADC offers lots of opportunities for you to get involved.

Research studies generally fall in three main categories:

  • Discovery and Innovation Studies
  • Investigational Medicine Trials
  • Exercise and Lifestyle Intervention Trials

To learn more or to enroll in a study or clinical trial, visit the KU ADC website.


Our Neuromuscular Division is one of the largest and most active research and clinical trial units in North America. We engage in a range of local, national and international studies on variety of neuromuscular diseases and conditions.

Our mission is to better understand the natural history of disease; improve our knowledge of disease biomarkers; and to translate research advances into improved diagnoses, care and educational resources for people with neuromuscular diseases.

Here are some of the areas we study.

  • Amyotrophic Lateral Sclerosis (ALS)
  • Myasthenia Gravis/ Lambert-Eaton Myasthenic Syndrome (LEMS)
  • Neuropathy
  • Myositis
  • Duchenne Muscular Dystrophy
  • LGMD
  • Facioscapulohumeral muscular dystrophy (FSHD)
  • Pompe
  • Myotonic Dystrophy

Visit our website to learn more about us and our currently enrolling studies.

Last modified: Apr 14, 2021